Synthesis and antisense activity of oligonucleotides modi®ed with 2¢-O- [2-[(N,N-dimethylamino)oxy]-ethyl] (2¢-O-DMAOE) are described. The 2¢-O-DMAOE-modi®ed oligonucleotides showed superior metabolic stability in mice. The phosphorothioate oligonucleotide`gapmers', with 2¢-O-DMAOEmodi®ed nucleoside residues at the ends and 2¢-deoxy nucleosides residues in the central region, showed dose-dependent inhibition of mRNA expression in cell culture for two targets.`Gapmer' oligonucleotides have one or two 2¢-O-modi®ed regions and a 2¢-deoxyoligonucleotide phosphorothioate region that allows RNase H digestion of target mRNA. To determine the in vivo potency and ef®-cacy, BalbC mice were treated with 2¢-O-DMAOE gapmers and a dose-dependent reduction in the targeted C-raf mRNA expression was observed. Oligonucleotides with 2¢-O-DMAOE modi®cations throughout the sequences reduced the intercellular adhesion molecule-1 (ICAM-1) protein expression very ef®ciently in HUVEC cells with an IC 50 of 1.8 nM.
INTRODUCTION
Antisense oligonucleotides have proven effective in inhibiting a number of viral and cellular gene products, both in vitro and in vivo (1±5). The activity of antisense oligonucleotides depends upon many factors, including binding af®nity to target RNA, nuclease resistance, and cellular absorption and modulate the protein binding of oligonucleotides (4, 6) . To optimize activity, structural analogs of nucleic acids with modi®ed heterocycle, sugar and phosphodiester backbone moieties have been synthesized (6,7±12) . Some of the most successful analogs resulted from modi®cation of the sugar at the 2¢ position (6, 11) . The 2¢-O-modi®ed oligonucleotides used with the`gapmer' technology (13) have emerged as the leading second generation candidates for clinical applications.`Gapmer' oligonucleotides have one or two 2¢-O-modi®ed regions and a 2¢-deoxyoligonucleotide phosphorothioate region that allows RNase H digestion of the targeted mRNA.
Among the various 2¢-O-modi®ed oligonucleotides reported in the literature, the 2¢-O-(2-methoxyethyl)-modi®ed oligonucleotides (2¢-O-MOE) offer a 2°C increase in melting temperature (T m ) per modi®cation as a diester (2¢-O-MOE/ P=O) compared with the 2¢-deoxyphosphorothioate (2¢-H/ P=S) compounds (14) . This modi®cation with a phosphodiester linkage exhibits resistance to snake venom phosphodiesterase (measured as the half-life of disappearance of the full-length oligonucleotide, t 1/2 ) at approximately the same level as a 2¢-deoxyoligonucleotide phosphorothioate, the ®rst generation antisense drug. There are several 2¢-O-MOE antisense oligonucleotides in clinical trials (15) . We recently reported the synthesis of 2¢-O- [2- Fig. 1) , a new carbohydrate modi®c-ation that exhibits high binding af®nity towards target RNA and high nuclease resistance in a snake venom phosphodiesterase assay (16) . Recently, we published a convenient synthetic strategy for the synthesis of 2¢-O-DMAOE-modi®ed nucleoside phosphoramidites (Fig. 2) useful for all bases (17) . Here, we report the in vivo nuclease resistance and ability to inhibit target mRNA expression in vitro and in vivo of 2¢-O-DMAOE oligonucleotides. We also report the ef®cacy of uniformly modi®ed 2¢-O-DMAOE oligonucleotides in interfering with the formation of translational initiation complex of the translational machinery (15) . A comparative analysis of in vitro and in vivo antisense activity of 2¢-O-DMAOE oligonucleotides with that of 2¢-O-MOE oligonucleotides are also presented in this report.
[(N,N-dimethylamino)oxy]-ethyl] (2¢-O-DMAOE) (

MATERIALS AND METHODS
Oligonucletotide synthesis
2¢-O-DMAOE amidites 1±4 (Fig. 2 ) and 2¢-O-MOE amidites were synthesized as reported (14, 16, 17) . The standard phosphoramidites and solid supports were used for incorporation of A, T, G and 5-methyl C residues. A 0.1 M solution of the amidites in anhydrous acetonitrile was used for the synthesis of modi®ed oligonucleotides. The oligonucleotides (Table 1) were synthesized on functionalized controlled pore glass on an automated solid phase DNA synthesizer with ®nal DMT group retained at the 5¢ end. For incorporation of 2¢-O-DMAOE amidites, 6 equivalents of phosphoramidite solutions were delivered in two portions, each followed by a 5 min coupling wait time. All other steps in the protocol supplied by the manufacturer were used without modi®cation. Oxidation of the internucleotide phosphite to the phosphate was carried out using tert-butyl hydroperoxide/acetonitrile/ water (10:87:3) with a 10 min oxidation wait time, or iodine/ tetrahydrofuran/pyridine/water or 1-S-(+)-(10-camphorsulfonyl)oxaziridine, 0.5 M in acetonitrile (CSO), with a 4 min oxidation wait time. The Beaucage reagent (0.1 M in acetonitrile) was used as a sulfurizing agent. The coupling ef®ciencies were >97%. After completion of the synthesis, the solid support was suspended in aqueous ammonium hydroxide (28±30 wt%) and kept at room temperature for 2 h. The solid support was ®ltered and the ®ltrate was heated at 55°C for 6 h to complete the removal of all protecting groups. Crude oligonucleotides were puri®ed by high performance liquid chromatography (HPLC; Waters C-4 column, 7.8 Q 300 mm, 15 micron, 300 A Ê , A = 100 mM ammonium acetate, pH 6.5±7, B = acetonitrile, 5±60% of B in 55 min,¯ow 2.5 ml min ±1 , l = 260 nm). Detritylation was achieved by adjusting the pH of the solution to 3.8 with acetic acid and keeping at room temperature until complete removal of the trityl group, as monitored by HPLC analysis. The oligonucleotides were then desalted by HPLC to yield 2¢-modi®ed oligonucleotides in 30± 40% isolated yield calculated based on the loading of the 3¢-base to solid support (18) . The oligonucleotides were characterized by electrospray mass spectroscopy and their purity was assessed by HPLC (Table 2 ) and capillary gel electrophoresis (CGE).
In vivo nuclease stability assay
The 2¢-O-MOE gapmer oligonucleotides 5 and 6 (Table 1) and 2¢-O-DMAOE gapmer oligonucleotides 7 and 8 (Table 1) were administered to BalbC mice by i.p. injection at a 50 mg/kg dose. Oligonucleotide concentrations were calculated from the oligonucleotide absorbance at 260 nm and extinction coef®cients estimated according to Puglisi and Tinoco (19) . After 24 h, mice were killed and the oligonucleotides were isolated from liver, kidney and spleen as described (20) . Samples were analyzed using a Beckman PA/CE System Gold 5010 capillary electrophoresis system with detection at 260 nm. Samples were loaded electrokinetically by application of 5±10 kV for 5±30 s, depending on the relative sample concentration. Separations were achieved operating at 10±15 kV constant voltages for between 6 and 10 min at 50°C. The percentage of full-length oligonucleotides in each organ was determined by integration of the peak area corresponding to the full-length oligonucleotide relative to the T 27 phosphorothioate internal standard at 200 nM.
Inhibition of protein kinase C-a (PKC-a) mRNA expression in vitro by 2¢-O-DMAOE gapmer oligonucleotides
PKC-a mRNA expression in C127 cells was evaluated as described (21, 22) . Muraine C127 mammary epithelial cells were obtained from American Type Culture Collection. C127 cells were grown in T-75¯asks in Dulbecco's modi®ed Eagle's medium containing 1 g of glucose per liter (DMEM; GIBCO/BRL), and 10% fetal bovine serum (FBS; HyCLone) until 70±80% con¯uent. Cells were washed twice in 10 ml of DMEM. Then, 5 ml of DMEM containing N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride/ dioleoyl phosphatidylethanolamine (DOTMA/DOPE) solution (Lipofectin; ®nal concentration, 20 mg/ml; GIBCO/BRL) was added. Oligonucleotides 9 and 10 were then added to the required concentration. The cells were incubated at 37°C for 4 h, washed once with DMEM/10% FBS to remove the DOTMA/DOPE solution, and then allowed to recover for 72 h. Total mRNA was isolated from tissue culture cells by lysis in 4 M guanidinium isothiocyanate followed by cesium chloride gradient centrifugation (23) . RNA (20±40 mg) was resolved in 1.2% agarose gels containing 1.1% formaldehyde and transferred to nylon membranes. The blots were then hybridized with bovine PKC-a cDNA (American Type Culture Collection) as described (24) . Probe hybridized to mRNA transcript was visualized and quantitated with a PhosphorImager (Molecular Dynamics). PKC-a mRNA is expressed as two transcripts, 8.5 and 4.0 kb. The blots were then stripped of radioactivity by boiling and reprobed with a 32 P-labeled glycerol-3-phosphate dehydrogenase (G3PDH) probe (Clontech) to con®rm equal loading. 
Inhibition of ICAM-1 protein expression of 2¢-O-DMAOE oligonucleotides in vitro
Quantitation of ICAM-1 protein expression in HUVEC cells was carried out as described (25) . HUVEC cells were purchased from Clonetics Corp. (San Diego, CA) and cultured in EBM medium (HyClone) supplemented with 10% fetal bovine serum. Cells used for experiments were from passages two to 10 at 80±90% con¯uency. Cells were washed three times with Opti-MEM (Life Technologies, Inc.) pre-warmed to 37°C. Oligonucleotides 11±14 (Table 1) were premixed with 10 mg/ml Lipofectin (Life Technologies, Inc.) in opti-MEM, serially diluted to the desired concentrations and applied to the washed cells. Basal and untreated (no oligonucleotides) control cells were also treated with Lipofectin. Cells were incubated for 4 h at 37°C, at which time the medium was removed and replaced with standard growth medium with or without 5 ng/ml IL-1 b and incubated at 37°C overnight. Cells were removed from the plate surfaces by brief trypsinization with 0.25% trypsin in PBS. Trypsin activity was quenched with a solution of 25% bovine serum albumin and 0.2% sodium azide in PBS (+Mg/Ca). Cells were pelleted by centrifugation (1000 r.p.m.; Beckman GPR centrifuge), resuspended in PBS, and stained with 3 ml/10 5 cells of the ICAM-1-speci®c antibody, CD54-PE (Becton Female BALB/c mice (6 weeks old; Harlan Sprague±Dawley, Indianapolis, IN) were housed three to a cage under conditions meeting National Institute of Health regulations (26) . Oligonucleotides 5±8 were administered in 0.9% NaCl, i.p. at indicated dose levels once daily for 3 days and tissues were harvested for analysis. Total mRNA was extracted from mouse liver by rapid homogenization of the tissue in 4 M guanidinium isothiocyanate followed by centrifugation over a cesium chloride gradient. RNAs (20±40 mg) were resolved in 1.2% agarose gels containing 1.1% formaldehyde and transferred to nylon membranes. The blots were hybridized with a radiolabeled human C-raf-1 cDNA probe as described (21) . Probes hybridized to mRNA transcripts were visualized and quanti®ed using a PhosphorImager. After stripping the blots of radiolabeled probe, they were re-probed with G3PDH cDNA to con®rm equal loading.
RESULTS AND DISCUSSION
Nuclease stability of modi®ed oligonucleotides in vivo
The in vivo metabolic stability of antisense drugs is crucial for the desired pharmacological effect. The naturally occurring oligonucleotide phosphodiesters are rapidly degraded in biological¯uids by nucleases (15) . Chemical modi®cations at the backbone, sugar and/or base have been shown to stabilize oligonucleotides to enzymatic digestion with a t 1/2 5¢-(T*oC*oT*oG*oA*oG*oT*oA*oG*oC*oA*oG*oA*oG*oG*oA*oG*oC*oT*oC*)-3¢ ICAM-1 15 The oligonucleotides 5±8 were administered to BalbC mice by i.p. injection at a 50 mg/kg dose. After 24 h, mice were killed and the oligonucleotides were isolated from liver, kidney and spleen. The percentage of full-length oligonucleotides in each organ (Fig. 3) was determined by CGE analysis. After 24 h, 80±100% of full-length phosphorothioate oligonucleotides 5 and 7 were isolated from these organs, whereas only 25±40% of mixed backbone oligonucleotides 6 and 8 was isolated. The role of 2¢-O-DMAOE modi®cation in enhancing the stability of oligonucleotides against exonuclease-mediated degradation has been reported (16, 17) . The observed in vivo metabolic stability of oligonucleotides with 2¢-O-DMAOE modi®cations is consistent with the reported in vitro metabolic stability of 2¢-O-DMAOE-modi®ed oligonucleotides. These data suggest that antisense drugs with 2¢-O-DMAOE modi®cations would be available for pharmacological action longer than 24 h. This also implies that antisense drugs with 2¢-O-DMAOE modi®cations will exhibit pharmacology with a lesser number of doses compared with ®rst generation antisense drugs.
Effect of 2¢-O-DMAOE-modi®ed oligonucleotides on PKC-a mRNA expression in C127 cells
In order to evaluate the ef®cacy of inhibition of gene expression via RNase H digestion of target mRNA, a 2¢-O-DMAOE gapmer oligonucleotide 10, targeting human serine/ threonine-speci®c PKC-a expression (21,22) was synthesized.
For comparison, we synthesized the previously characterized 2¢-O-MOE gapmer 9 of the same sequence. The serine/ threonine-speci®c PKC family members regulate a variety of cellular responses, including proliferation, differentiation and apoptosis (27, 28) . The oligonucleotide 10 reduced the expression of PKC-a mRNA in human C127 cells (Fig. 4) with an IC 50 of 33.4 nM ( Table 3) and was 2.4-fold more potent than the 2¢-O-MOE gapmer 9 (IC 50 80.6 nM, Table 3 ). This increase in potency correlates well with the superior binding demonstrated by the 2¢-O-DMAOE-modi®ed oligonucleotides (16, 17) .
Effect of 2¢-O-DMAOE-modi®ed oligonucleotides on inhibition of the ICAM-1 translation initiation complex in HUVEC cells
2¢-O-MOE-modi®ed oligonucleotides 11 and 13 have been shown to selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translational initiation complex in HUVEC cells (25) . The inhibition of protein expression by these oligonucleotides is due to selective interference with the formation of 80 S translational initiation complexes. We have synthesized fully modi®ed 2¢-O-DMAOE oligonucleotides 12 and 14 (Table 1 ) and compared their activity with 2¢-O-MOE oligonucleotides 11 and 13 ( Table 1 ). The oligonucleotides were analyzed for inhibition of IL-1b-stimulated ICAM-1 protein expression in HUVEC cells. These antisense oligonucleotides exhibited dosedependent reduction of ICAM-1 protein expression very Table 3 ). The activities of the 2¢-O-DMAOE-modi®ed oligonucleotides were slightly better than those observed for 2¢-O-MOE-modi®ed oligonucleotides. These data suggest that 2¢-O-DMAOE-modi®ed oligonucleotides could be potentially useful as agents to inhibit translation by steric blockade.
Inhibition of C-raf mRNA expression in mouse liver after systemic administration of phosphorothioate
2¢-O-DMAOE-modi®ed oligonucleotides
The phosphorothioate oligonucleotide 17 (Table 1) was previously characterized as a potent inhibitor of C-raf kinase expression (29) . In the current study, the same sequence with 2¢-O-MOE and 2¢-O-DMAOE gapmer constructs (5±8) ( Table 1) were used to target C-raf mRNA in female Balb C mice. The female Balb/C mice were administered oligonucleotides 5±8 at 3, 10, 25 and 50 mg/kg, once daily for 3 days. The mice were killed and the tissue was harvested for analysis. Total mRNA was isolated. The mRNA levels were quantitated by northern blot and PhosphorImager analysis. The phosphorothioate 2¢-O-DMAOE gapmer oligonucleotide (7) was a potent inhibitor of C-raf mRNA in mouse liver (Fig. 6) , with activity comparable to the 2¢-O-MOE gapmer oligonucleotide 5 (Fig. 6 ). The oligonucleotides 6 and 8 with mixed backbone chemistry were not effective in inhibition of C-raf mRNA expression in vivo. It has been reported that 2¢-O-MOE modi®cation combined with phosphodiester backbone exhibited 10-fold more rapid plasma clearance compared with the corresponding oligonucleotide phosphorothioates (30) . The lack of activity with mixed backbone gapmer oligonucleotides (6 and 8) may be attributed to their rapid plasma clearance, and as a result, poor tissue distribution of these oligonucleotides.
In conclusion, oligonucleotides with 2¢-O-DMAOE modi®cations were synthesized with phosphorothioates (PS) and mixed backbone (PO/PS) chemistries. The uniformly modi®ed 2¢-O-DMAOE oligonucleotides were also synthesized in good yield. The 2¢-O-DMAOE modi®cation improved the in vivo metabolic stability of the olignucleotides compared with ®rst generation antisense oligonucleotides. The 2¢-O-DMAOEmodi®ed gapmers were 2-fold more potent than 2¢-O-MOE oligonucleotides in inhibition of gene expression in vitro. The uniformly modi®ed 2¢-O-DMAOE oligonucleotide inhibited ICAM-1 protein expression in vitro, presumably by interfering with the formation of the translational initiation complex at a level comparable with the 2¢-O-MOE. The 2¢-O-DMAOE gapmer oligonucleotide phosphorothioates designed to inhibit C-raf expression in mice showed very good potency, again comparable with the 2¢-O-MOE gapmer. In summary, we have demonstrated the ef®cacy of the 2¢-O-DMAOE-modi®ed oligonucleotides in reducing the targeted message in vitro and in vivo. The 2¢-O-DMAOE-modi®ed oligonucleotides support inhibition of gene expression by the RNase H-mediated mechanism and by interfering with the translational initiation machinery. Our study demonstrates that 2¢-O-DMAOE-modi®ed oligonucleotides should be valuable for inhibition of gene expression using either an RNase H-dependent or RNase H-independent mechanism. . Reduction of C-raf mRNA in mouse liver after administration of 2¢-O-MOE oligonucleotides 5 and 6 and 2¢-O-DMAOE oligonucleotides 7 and 8. C-raf mRNA levels were determined by northern blot analysis. C-raf mRNA was quanti®ed by PhosphorImager analysis and normalized to G3PDH mRNA levels.
